Alvaro Amorrortu has been building and leading high performing teams for the past 20 years. He acquired a wealth of experience and knowledge during his tenure at Solid Biosciences. In his role as Chief Operating Officer, he led and managed the infrastructure build-up to support a gene therapy clinical trial in Duchenne Muscular Dystrophy. Prior to Solid Biosciences, Alvaro was a strategy consultant for bio-pharma companies. He was at The Monitor Group (now Monitor Deloitte) for a decade and then became Vice President in the Boston office of Campbell Alliance (the consulting arm of Syneos Health).

Alvaro holds degrees from the The Wharton School of the University of Pennsylvania (MBA) and Instituto Tecnologico de Buenos Aires (MS Engineering).

Dr. Roderick Slavcev is the founder and Chief Science Officer of Mediphage Bioceuticals and brings over 25 years of research experience in both academic and industrial settings. He is a co-inventor of Mediphage’s ministring DNA platform technology and is responsible for planning and directing all aspects of the organization’s technical product, platform, and solutions. Dr. Slavcev continues to guide ongoing product development, strategic direction, and applications of the core technology.

Dr. Slavcev is a Chartered Biologist and has a PhD in microbial genetics from University of Waterloo and an MBA in biotechnology management from University of Saskatchewan.